Phosphodiesterase type 4 inhibitors, but not glucocorticoids, are more potent in suppression of cytokine secretion by mononuclear cells from atopic than nonatopic donors

Journal of Allergy and Clinical Immunology

Volumn 102, Issue 5, 1998, Pages 797-804

  Crocker, I Caroline ^a   Ohia, S Edet ^b   Church, Martin K ^c   Townley, Robert G ^a,d  

^a Department of Medicine   (United States)

^b Department of Pharmaceutical and Administrative Sciences ^*  (United States)

^c SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^d CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atopic; Cytokines; Glucocorticoids; IL 10; Phosphodiesterase inhibitors; TNF

Indexed keywords

4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; BECLOMETASONE DIPROPIONATE; CYTOKINE; GLUCOCORTICOID; INTERLEUKIN 10; MOMETASONE FUROATE; PHOSPHODIESTERASE IV INHIBITOR; ROLIPRAM; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATOPY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOREGULATION; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0031753056     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-6749(98)70020-X     Document Type: Article

References (47)

1. Dent G, Giembycz MA. Phosphodiesterase inhibitors: Lily the Pink's medicinal compound for asthma? Thorax 1996;51:647-9.
2. Crocker IC, Townley RG, Khan MM. Phosphodiesterase inhibitors suppress proliferation of peripheral blood mononuclear cells and interleukin4 and -5 secretion by human T-helper type 2 cells. Immunopharmacology 1996;31:223-35.
3. Tanimoto Y, Maruo H, Bewtra AK, Townley RG. Effects of phosphodiesterase IV inhibitor (WAY-PDA-641) on human eosinophil and neutrophil migration in vitro [abstract], J Allergy Clin Immunol 1994;93:A570.
4. Brinkmann V, Kristofic C. Regulation by corticosteroids of Th1 and Th2 cytokine production in human CD4+ effector T cells generated from CD45RO- and CD45RO+ subsets. J Immunol 1995;155:3322-8.
5. Crocker IC, Zhou CY, Bewtra AK, Kreutner W, Townley RG. Glucocorticosteroids inhibit leukotriene production. Ann Allergy Asthma Immunol 1997;78:497-505.
6. Crocker IC, Newton S, Townley RG. Glucocorticoids inhibit cytokine secretion and proliferation by T-cells [abstract], J Allergy Clin Immunol 1997;99:S331.
7. Crocker IC, Townley RG. Interleukin-10 secretion is inhibited by phosphodiesterase inhibitors and glucocorticoids in vitro [abstract]. Am J Respir Crit Care Med 1997;155:A751.
8. Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1989;170:2081-95.
9. de Waal Malefyt R, Yssel H, de Vries JE. Direct effects of IL-10 on subsets of human CD4+ T cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation. J Immunol 1993;150:4754-65.
10. de Waal Malefyt R, Haanen J, Spits H, Roncarolo MG, te Velde A, Figdor C, et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991;174:915-24.
11. Kambayashi T, Jacob CO, Zhou D, Mazurek N, Fong M, Strassmann G. Cyclic nucleotide phosphodiesterase type IV participates in the regulation of IL-10 and in the subsequent inhibition of TNF-α and IL-6 release by endotoxin-stimulated macrophages. J Immunol 1995;155:4909-16.
12. Del Prete G, De Carli M, Almerigogna F, Giudizi MG, Biagiotti R, Romagnani S. Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J Immunol 1993;150:353-60.
13. Wanidworanun C, Strober W. Predominant role of tumor necrosis factorα in human monocyte IL-10 synthesis. J Immunol 1993;151:6853-61.
14. van der Poll T, Coyle SM, Barbosa K, Braxton CC, Lowry SF. Epinephrine inhibits tumor necrosis factor-α and potentiates interleukin 10 production during human endotoxemia. J Clin Invest 1996;97:713-9.
15. Tabardel Y, Duchateau J, Schmartz D, Marecaux G, Shahla M, Barvais L, et al. Corticosteroids increase blood interleukin-10 levels during cardiopulmonary bypass in men. Surgery 1996;119:76-80.
16. van Furth AM, Seijmonsbergen EM, Langermans JA, van der Meide PH, van Furth R. Effect of xanthine derivates and dexamethasone on Streptococcus pneumoniae-stimulated production of tumor necrosis factor α, interleukin-1 β(IL-1 β), and IL-10 by human leukocytes. Clin Diagn Lab Immunol 1995;2:689-92.
17. Kunicka JE, Talle MA, Denhardt GH, Brown M, Prince LA, Goldstein G. Immunosuppression by glucocorticoids: inhibition of production of multiple lymphokines by in vivo administration of dexamethasone. Cell Immunol 1993;149:39-49.
18. Prabhakar U, Lipshutz D, Bartus JO, Slivjak MJ, Smith EF, Lee JC, et al. Characterization of cAMP-dependent inhibition of LPS-induced TNF α production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor. Int J Immunopharmacol 1994;16:805-16.
19. Ravid A, Tamir R, Liberman UA, Rotem C, Pick AI, Novogrodsky A, et al. 1,25-Dihydroxyvitamin D3 potentiates the decreased response of lymphocytes from atopic subjects to agents that increase intracellular cyclic adenosine monophosphate. J Allergy Clin Immunol 1990;86:881-5.
20. Essayan DM, Huang SK, Undem BJ, Kagey Sobotka A, Lichtenstein LM. Modulation of antigen- and mitogen-induced proliferative responses of peripheral blood mononuclear cells by nonselective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors. J Immunol 1994;153:3408-16.
21. Chan SC, Hanifin JM. Differential inhibitor effects on cyclic adenosine monophosphate-phosphodiesterase isoforms in atopic and normal leukocytes. J Lab Clin Med 1993;121:44-51.
22. Kam JC, Szefler SJ, Surs W, Sher ER, Leung DY. Combination IL-2 and IL-4 reduces glucocorticoid receptor-binding affinity and T cell response to glucocorticoids. J Immunol 1993;151:3460-6.
23. Nimmagadda SR, Szefler SJ, Spahn JD, Surs W, Leung DY. Allergen exposure decreases glucocorticoid receptor binding affinity and steroid responsiveness in atopic asthmatics. Am J Respir Crit Care Med 1997;155:87-93.
24. Barnes PJ, Greening AP, Crompton GK. Glucocorticoid resistance in asthma. Am J Respir Crit Care Med 1995;152:S125-40.
25. Crocker IC, Ohia SE, Church MK, Townley RG. Phosphodiesterase type 4 inhibitors, but not glucocorticoids, are more potent in suppression of cytokine secretion by mononuclear cells from atopic than nonatopic donors [abstract]. J Allergy Clin Immunol 1998;101:S143.
26. Banner KH, Roberts NM, Page CP. Differential effect of phosphodiesterase 4 inhibitors on the proliferation of human peripheral blood mononuclear cells from normals and subjects with atopic dermatitis. Br J Pharmacol 1995;116:3169-74.
27. Spahn JD, Landwehr LP, Nimmagadda S, Surs W, Leung DY, Szefler SJ. Effects of glucocorticoids on lymphocyte activation in patients with steroid-sensitive and steroid-resistant asthma. J Allergy Clin Immunol 1996;98:1073-9.
28. Schumacher JH, O'Garra A, Shrader B, van Kimmenade A, Bond MW, Mosmann TR, et al. The characterization of four monoclonal antibodies specific for mouse IL-5 and development of mouse and human IL-5 enzyme-linked immunosorbent. J Immunol 1988;141:1576-81.
29. Barnes PJ. Cyclic nucleotides and phosphodiesterases and airway function. Eur Respir J 1995;8:457-62.
30. Seldon PM, Barnes PJ, Meja K, Giembycz MA. Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase. Mol Pharmacol 1995;48:747-57.
31. Rieckmann P, Weber E, Gunther A, Martin S, Bitsch A, Broocks A, et al. Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis. J Neuroimmunol 1996;64:193-200.
32. Brackeen ME, Cowan DJ, Stafford JA, Schoenen FJ, Veal JM, Domanico PL, et al. Design and synthesis of conformationally constrained analogues of 4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one (Ro 20-1724) as potent inhibitors of cAMP-specific phosphodiesterase. J Med Chem 1995;38:4848-54.
33. Hartman DA, Ochalski SJ, Carlson RP. The effects of antiinflammatory and antiallergic drugs on cytokine release after stimulation of human whole blood by lipopolysaccharide and zymosan A. Inflamm Res 1995;44:269-74.
34. Jacobitz S, McLaughlin MM, Livi GP, Burman M, Torphy TJ. Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding. Mol Pharmacol 1996;50:891-9.
35. Essayan DM, Huang SK, Kagey Sobotka A, Lichtenstein LM. Differential efficacy of lymphocyte- and monocyte-selective pretreatment with a type 4 phosphodiesterase inhibitor on antigen-driven proliferation and cytokine gene expression. J Allergy Clin Immunol 1997;99:28-37.
36. Sette C, Conti M. Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase. Involvement of serine 54 in the enzyme activation. J Biol Chem 1996;271:16526-34.
37. Sette C, Vicini E, Conti M. The ratPDE3/IVd phosphodiesterase gene codes for multiple proteins differentially activated by cAMP-dependent protein kinase [published erratum appears in J Biol Chem 1994;269:20806]. J Biol Chem 1994;269:18271-4.
38. Chan SC, Reifsnyder D, Beavo JA, Hanifin JM. Immunochemical characterization of the distinct monocyte cyclic AMP-phosphodiesterase from patients with atopic dermatitis. J Allergy Clin Immunol 1993;91:1179-88.
39. Hanifin JM, Chan SC, Cheng JB, Tofte SJ, Henderson WR Jr, Kirby DS, et al. Type 4 phosphodiesterase inhibitors have clinical and in vitro antiinflammatory effects in atopic dermatitis. J Invest Dermatol 1996;107:51-6.
40. Abbas AK, Lichtman AH, Pober JS. Molecular basis of T cell antigen recognition and activation. In: Cellular and molecular immunology. Philadelphia: W.B. Saunders Company; 1994. p. 136-65.
41. Rousset F, Robert J, Andary M, Bonnin JP, Souillet G, Chretien I, et al. Shifts in interleukin-4 and interferon-γ production by T cells of patients with elevated serum IgE levels and the modulatory effects of these lymphokines on spontaneous IgE synthesis. J Allergy Clin Immunol 1991;87:58-69.
42. Paliogianni F, Raptis A, Ahuja SS, Najjar SM, Boumpas DT. Negative transcriptional regulation of human interleukin 2 (IL-2) gene by glucocorticoids through interference with nuclear transcription factors AP-1 and NF-AT. J Clin Invest 1993;91:1481-9.
43. Yu XP, Bellido T, Manolagas SC. Down-regulation of NF-κ B protein levels in activated human lymphocytes by 1,25-dihydroxyvitamin D3. Proc Natl Acad Sci USA 1995;92:10990-4.
44. Pindolia KR, Noth CJ, Xu YX, Janakiraman N, Chapman RA, Gautam SC. IL-4 upregulates IL-1-induced chemokine gene expression in bone marrow stromal cells by enhancing NF-κB activation. Hematopathol Mol Hematol 1996;10:171-85.
45. Crocker IC, Church MK, Newton S, Townley RG. Glucocorticoids inhibit proliferation and interleukin-4 and -5 secretion by aeroallergen-specific T-helper type 2 cell lines. Ann Allergy Asthma Immunol 1998. In press.
46. Umland SP, Nahrebne DK, Razac S, Beavis A, Pennline KJ, Egan RW, et al. The inhibitory effects of topically active glucocorticoids on IL-4, IL-5, and interferon-γ production by cultured primary CD4+ T cells. J Allergy Clin Immunol 1997;100:511-9.
47. Borish L, Aarons A, Rumbyrt J, Cvietusa P, Negri J, Wenzel S. Interleukin-10 regulation in normal subjects and patients with asthma. J Allergy Clin Immunol 1996;97:1288-96.